Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading – CNBC June 5, 2023
Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 – Endpoints News June 5, 2023
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – Moderna Investor Relations April 16, 2023
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – news.modernatx.com April 16, 2023
Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and more – CNBC March 13, 2023
Moderna Stock Skids After 2023 Guidance Misses By More Than $2 Billion – Investor’s Business Daily February 23, 2023
Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand – CNBC February 23, 2023
Moderna Pops On An FDA Boon For Its Merck-Tied Cancer Vaccine – Investor’s Business Daily February 22, 2023
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients – Moderna Investor Relations February 22, 2023